CSF somatostatin immunoreactivity and GH plasma levels in Alzheimer's disease

L. Steardo, C. A. Tamminga, P. Barone

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Growth hormone (GH) plasma levels over 24 hours were studied in 9 subjects with Alzheimer's disease and in 8 healthy volunteers. No significant difference occurred between two groups. Conversely, levels of somatostatin immunoreactivity (SRIF-IR) were significantly lower in lumbar cerebrospinal fluid (CSF) of the patients compared to the controls, suggesting that the hypothalamus is relatively spared and the lack of any correlation between hypothalamic somatostatin and CSF SRIF-IR.

Original languageEnglish (US)
Pages (from-to)291-294
Number of pages4
JournalNeuroendocrinology Letters
Issue number5
StatePublished - Jan 1 1984

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Neurology
  • Endocrine and Autonomic Systems
  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'CSF somatostatin immunoreactivity and GH plasma levels in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this